

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



MicroPort CardioFlow Medtech Corporation

微创心通医疗科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2160)

ADOPTION OF NEW SHARE SCHEME

The board of directors (the “**Board**”) of MicroPort CardioFlow Medtech Corporation (the “**Company**”) proposes to adopt a new share scheme (the “**Share Scheme**”) in compliance with the amendments to Chapter 17 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited that came into effect on January 1, 2023.

The purpose of the Share Scheme is to enable the Company to provide incentives to eligible participants for their contribution or potential contribution to the Company and/or any of its subsidiaries.

The Share Scheme is subject to, among other things, the approval of the shareholders of the Company at a general meeting of the Company to be convened for the purpose of considering and, if thought fit, approving the adoption of the Share Scheme.

Further details about the Share Scheme, including its principal terms, will be set out in the circular of the Company to be despatched to the shareholders of the Company in due course.

Reference is made to the announcement of the Company dated March 30, 2023 (the “**Announcement**”) in relation to grant of options. The Company would like to clarify that the date of grant of options is March 30, 2023. Save as disclosed above, all information in the Announcement remains unchanged.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Luo Qiyi
Chairman

Shanghai, PRC, March 31, 2023

As at the date of this announcement, the executive Directors are Mr. Chen Guoming, Mr. Zhao Liang and Ms. Yan Luying, the non-executive Directors are Dr. Luo Qiyi, Mr. Zhang Junjie and Ms. Wu Xia, and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Ding Jiandong and Ms. Sun Zhixiang.